Protocols
73 protocol(s) meet the specified criteria
Disease Site: Breast
Protocol No.TitleStatus
13-0736 Improving endocrine therapy utilization in racially diverse populationsOpen
15-102-14A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and CapecitabineOpen
15-2304Implementing Breast Cancer Care Efficiency in Zambia through Specialized Health Provider Training and mhealth Evaluation of Patient OutcomesOpen
16-1634Comparative Effectiveness of Breast Cancer Screening, Diagnosis, and Management in Community PracticeOpen
16-1775Developing a Medication Assistance Program for Uninsured and Under-insured Patients with Metastatic Breast Cancer: Key Informant Conference Participant Data Open
17-2168Carolina Mammography Registry (CMR)Open
201209135A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast CancerOpen
A011401Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Open
A011502-CIRBA Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial Open
A171603Feasibility of an Electronic Geriatric Assessment (EGA) for Older Adults with CancerOpen
A211201-REXCHANGE IN MAMMOGRAPHIC DENSITY WITH METFORMIN USE: A COMPANION STUDY TO NCIC STUDY MA.32Open (affiliates only)
A221405A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE)Open
AFT-25Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: a Phase III Prospective Randomized TrialOpen
AFT-25-REXComparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: a Phase III Prospective Randomized TrialOpen
ALTERNATE/A011106ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III StudyOpen
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
B2151009Phase 1B Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)Open
DMT-2015-001A prospective, multicenter, multi-arm, clinical case collection program to acquire breast image data and establish an image library of exams for use in future research studies, training, marketing, and advance new product development effortsOpen
E1Z11A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)Open (affiliates only)
E2112-CIRBA Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast CancerOpen
EA1151Tomosynthesis Mammographic Imaging Screening Trial (TMIST)Open
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
INCAGN1876-201A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune therapies in Subjects with Advanced or Metastatic MalignanciesOpen
INO-VT-464-CL-006A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast CancerOpen
LCCC1405Comparison of the specificity of acoustic angiography (Micro-tumor detection by quantifying tumor-induced vascular abnormalities) to the specificity of conventional ultrasoundOpen
LCCC1410Impact of physical activity on biomarkers of aging and body composition among breast cancer survivors age 65 and older Open
LCCC1414Evaluation of stationary digital breast tomosynthesis in a screening call back population and in patients with calcifications Open
LCCC1419Establishment of Breast Cancer Brain Metastases (BCBM) Registry to Support Research of Molecular Drivers of BCBMOpen
LCCC1501The Impact of Real Time, Three-Dimensional Photographic Simulation on Satisfaction with Decisions about Breast Reconstruction Open
LCCC1512Evaluation of the accuracy of new-generation pedometers in older adult patients with advanced cancers Open
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1537Physical activity to maintain quality of life and physical function in women with metastatic breast cancer: a pilot studyOpen
LCCC1540Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation.Open
LCCC1545Computerized Cognitive Behavioral Therapy in Recently Treated Breast Cancer PatientsOpen
LCCC1611Establishment of a novel breast cancer cohort in MalawiOpen
LCCC1616Developing a medication assistance program for uninsured and underinsured patients with metastatic breast cancer Open
LCCC1618Validation of Activity Tracker Data as a Measure of Fatigue, Symptom Burden, Physical Function and Quality of Life in Adults Receiving Taxane Therapy for Treatment of Stage II/III Breast CancerOpen
LCCC1622A Single Arm Evaluation of False Negative Rate of Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1630Get Real and HEEL Research ProgramOpen
LCCC1631A Qualitative Study of Patients who chose Contralateral Prophylactic Mastectomy (CPM) Open
LCCC1639A Non-Randomized, Non-Comparative, Open-Label, Window Trial of Entinostat in Subjects with Borderline ER/PR Positive Breast Cancer and TNBC (Part 1) or Entinostat with or without Exemestane in Subjects with Newly Diagnosed, Stage I-IIIC, Hormone Receptor Positive (HR+) Breast Cancer (Part 2)Open
LCCC1642Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast CancerOpen
LCCC1701A Web-based Tailored Health Behavior Intervention for Breast and Colon Cancer Survivors (eWellness)Open
LCCC1719A Psychosocial Intervention to Improve Outcomes for Parents with Advanced CancerOpen
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
LCCC1737Leveraging Stakeholders’ Perspectives to Develop and Test Stakeholder Responsive Survivorship (StaRS), a Change Package for Optimizing Survivorship Care Implementation Open
LCCC1749Impact of home-based aerobic and strength exercises during chemotherapy for early breast cancer on biomarkers of aging and patient-reported symptoms and outcomesOpen
LCCC1801A Cognitive Neuroscience Based-Assessment of Breast Cancer Survivors and Healthy Control ParticipantsOpen
LCCC1802Randomized Trial of Parotid Sparing Whole Brain RadiationOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
MDT16075OsteoCool Tumor Ablation Post-Market Study (OPuS One)Open
MK-3475-355-REXA Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355)Open (affiliates only)
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
MM-121-02-02-10SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic TherapyOpen
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
NCI10013-CIRBRandomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)Open
NCI10020-CIRBA Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)Open
NRG-BR003-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast CancerOpen
NSABP-B-46-IA Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerOpen (affiliates only)
NSABP-B-54-I-REXPhase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapyOpen (affiliates only)
ONT-380-206Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)Open
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RETROSHAVEComparison of surgical techniques for obtaining negative margins in patients with breast cancerOpen
S1207-CIRBPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
S1416-CIRBPhase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases.Open
S1418-CIRBPhase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant ChemotherapyOpen
TBCRC-034The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Intraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle BiopsyOpen
TBCRC-037A Trial of Endocrine Response in Women with Invasive Lobular Breast CancerOpen
TBCRC038Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS ProgressionOpen
Z31602Z 31602 - Breast and Cervical Cancer Survivorship Among HIV-Positive Women in ZambiaOpen
Z31603A comparison of digital cervicography and transvaginal colposcopyOpen